The Clinical trials registered in Clinicaltrial.gov that involve ERN Members and Affiliated partners in at least two Member States are listed below.
| Monitoring period | Title | Members and Affiliated Partners | Member State(s) |
|---|---|---|---|
| 2024 | LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis | AOU Careggi, Florence; AOU Città della Salute e della Scienza di Torino; AOU Consorziale polyclinic - Bari; AOU Federico II - Naples; AOU Modena; AOU Ospedali Riuniti "Umberto I - G.M. Lancisi-G. Salesi"; AOU Policlinico Umberto I - Rome; AOU S.Luigi Gonzaga; AOU Siena; AOUI Verona; Academic Medical Center Amsterdam; Aghia Sophia Children's Hospital; Azienda Ospedaliero-Universitaria S. Anna di Ferrara; Azienda Ospedaliero-Universitaria di Parma; Erasmus MC: University Medical Center Rotterdam; Foundation polyclinic University A. Gemelli - Rome; IRCCS Ospedale Pediatrico Bambino Gesù, Roma; IRCCS Ospedale San Raffaele di Milano; Medical University of Vienna; Ospedale Papa Giovanni XXIII di Bergamo; Riuniti hospitals Villa Sofia-Cervello - Palermo; Universitair Ziekenhuis Antwerpen; University Medical Center Utrecht; Universitätsklinikum Carl Gustav Carus; Universitätsklinikum Freiburg; Universitätsklinikum Hamburg-Eppendorf; Universitätsklinikum Heidelberg; Universitätsklinikum Leipzig; Universitätsklinikum Würzburg. | Belgium, Germany, Italy, Netherlands |
| 2024 | A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion-Dependen... | Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Rheinisches Hämoglobinopathie-Konsortium (Universitätsklinikum Düsseldorf). | France, Germany. |
| 2024 | A Long-term Follow-up Study of Subjects with β-Thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001) | Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Rheinisches Hämoglobinopathie-Konsortium (Universitätsklinikum Düsseldorf). | France, Germany. |
| 2024 | A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent ß-Thalassemia | Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Rheinisches Hämoglobinopathie-Konsortium (Universitätsklinikum Düsseldorf). | France, Germany. |
| 2024 | A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease | Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Rheinisches Hämoglobinopathie-Konsortium (Universitätsklinikum Düsseldorf). | France, Germany. |
| 2024 | A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent ßThalassemia or Severe Sickle Cell Disease. | Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Rheinisches Hämoglobinopathie-Konsortium (Universitätsklinikum Düsseldorf). | France, Germany. |
| 2024 | P-SP420-THAL-01: An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- and β-thalassemia | Aghia Sophia Children's Hospital; Azienda Ospedaliero-Universitaria S. Anna di Ferrara; General Hospital of Athens "LAIKO". | Greece, Italy. |
| 2024 | A phase 2A study to evaluate the safety and pharmokokinetics of Luspatercept (ACE-536) in pediatric participants with beta-thalassemia | Aghia Sophia Children's Hospital; Ulm University Medical Center (UUMC). | Greece, Germany. |
| 2024 | A randomized, double-blind, placebo controlled phase 3 study to compare efficacy and safety Oral Azacitidine plus best supportive care versus as Maintenance Therapy in subject with Acute Myeloid Leukemia in complete remission | Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Erasmus MC: University Medical Center Rotterdam; Foundation IRCCS Polyclinic San Matteo, Pavia; Institute of Hematology and Blood Transfusion- Prague; Leiden University Medical Center; Radboud University Medical Center Nijmegen. | France, Italy, Netherlands |
| 2024 | Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTfreedom) | Aarhus University Hospital; Karolinska University Hospital. | Denmark, Sweden. |
| 2024 | Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma | CHU de Montpellier; Charité Universitätsmedizin Berlin; Hospital Universitari Vall d'Hebron; Jules Bordet Institute; Maria Sklodowska-Curie National Research Institute of Oncology; Ulm University Medical Center (UUMC); Universitätsklinikum Hamburg-Eppendorf. | Belgium, Germany, Spain, France, Poland |
| 2024 | An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib | ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine; Ulm University Medical Center (UUMC). | Germany, France, Italy |
| 2024 | Costellation 0610-02 MANIFEST: "A Phase1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis) - Study Number 0610-02 | ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; University Hospital Leuven. | Germany, France, Italy |
| 2024 | 10-day decitabine versus conventional chemotherapy ("3+7") followed by allografting in AML patients >= 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group | AOU Ospedali Riuniti "Umberto I - G.M. Lancisi-G. Salesi"; Radboud University Medical Center Nijmegen; University Hospital Liège; University Hospital Liège; University Hospital RWTH Aachen; Vilnius University Hospital Santaros Klinikos. | Belgium, Germany, Italy, Lithuania, Netherlands |
| 2024 | A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | General Hospital of Athens "LAIKO"; Jules Bordet Institute; Maria Sklodowska-Curie National Research Institute of Oncology. | Belgium, Greece, Poland |
| 2024 | DRIVE PK : A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency (AG348-C-003) | Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; University Medical Center Utrecht. | France, Netherlands |
| 2024 | A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; University Hospital Leuven; Universitätsklinikum Carl Gustav Carus. | Belgium, Germany, France, Italy |
| 2024 | A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A | CHU de Lille; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; HUS Helsinki University Hospital, Hospital District of Helsinki and Uusimaa; University Hospital Leuven; University Hospitals Saint-Luc. | Belgium, Finland, France |
| 2024 | Long-term Follow-up of Subjects with Transfusion-Dependent β-Thalassemia Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector | Assistance Publique Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; IRCCS Ospedale Pediatrico Bambino Gesù, Roma. | France, Italy |
| 2024 | A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies (CLIO-1) | Hospital Universitari Vall d'Hebron; Maria Sklodowska-Curie National Research Institute of Oncology; Medical University of Vienna. | Spain, Poland, Austria |
| 2024 | APOLLO: A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLine-based chemotherapy (AIDA regimen) for patients with newLy diagnosed, high-risk acute promyelocytic leukemia | Azienda Ospedaliero-Universitaria S. Anna di Ferrara; Spedali Civili di Brescia; Universitätsklinikum Carl Gustav Carus. | Germany, Italy |
| 2024 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND) | Foundation IRCCS Polyclinic San Matteo, Pavia; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Maria Sklodowska-Curie National Research Institute of Oncology; University of Debrecen. | Hungary, Italy, Poland |
| 2024 | A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) | AOU Careggi, Florence; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; CHU de Lille; Erasmus MC: University Medical Center Rotterdam; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; IRCCS Ospedale Pediatrico Bambino Gesù, Roma; IRCCS Ospedale Pediatrico Bambino Gesù- Roma; University Hospital Leuven. | Belgium, France, Italy, Netherlands |
| 2024 | PRESEV2 : Validation of a Predictive Score of Acute Chest Syndrome | Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; CUB-Hôpital Erasme. | France, Belgium |
| 2024 | A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA) | AOU Policlinico Umberto I - Rome; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis. | France, Italy |
| 2024 | A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence | AOU Policlinico Umberto I - Rome; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis. | France, Italy |
| 2024 | A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic | AOU Policlinico Umberto I - Rome; Aarhus University Hospital; CHU de Lille; CHU de Limoges; Charité Universitätsmedizin Berlin; Copenhagen University Hospital - Rigshospitalet; Foundation IRCCS Polyclinic San Matteo, Pavia; General Hospital of Athens "LAIKO"; Jules Bordet Institute; University Hospital Leuven; Universitätsklinikum Heidelberg. | Belgium, Germany, Denmark, France, Greece, Italy |
| 2024 | A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis | ASST Sette Laghi - Ospedale di Circolo, Varese; General Hospital of Athens "LAIKO"; Hospital Universitari Vall d'Hebron. | Spain, Greece, Italy |
| 2024 | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (IMROZ) | Aarhus University Hospital; Institute of Hematology and Blood Transfusion, Prague; Maria Sklodowska-Curie National Research Institute of Oncology; University Hospital Brno; Universitätsklinikum Heidelberg. | Czechia, Germany, Denmark, Poland |
| 2024 | Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | IRCCS Ospedale San Raffaele di Milano; Institut Curie; Institute of Hematology and Blood Transfusion, Prague; Maria Sklodowska-Curie National Research Institute of Oncology. | Czechia, France, Italy, Poland |
| 2024 | A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia (BEYOND) | Aghia Sophia Children's Hospital; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan. | Greece, Italy |
| 2024 | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients (NIVEAU) | Academic Medical Center Amsterdam; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; CHU de Lille; Charité Universitätsmedizin Berlin; Jules Bordet Institute; Maria Sklodowska-Curie National Research Institute of Oncology; Universitätsklinikum Hamburg-Eppendorf. | Belgium, Germany, France, Netherlands, Poland |
| 2024 | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients (NIVEAU) | Academic Medical Center Amsterdam; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; CHU de Lille; Charité Universitätsmedizin Berlin; Jules Bordet Institute; Maria Sklodowska-Curie National Research Institute of Oncology; Universitätsklinikum Hamburg-Eppendorf. | Belgium, Germany, France, Netherlands, Poland |
| 2024 | Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) (BMN 270-301) | Assistance Publique-Hôpitaux de Marseille; CHU de Lille; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Hospital Universitario Virgen del RocÃo; University Hospital Leuven. | Belgium, France, Spain |
| 2024 | Extended access of Momelotinib for subjects with primar myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) | Fondazione IRCCS San Gerardo dei Tintori; Ordensklinikum Linz Elisabethinen; University Hospital Liège. | Belgium, Italy, Austria |
| 2024 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | AO Padua; AOU Modena; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; CUB-hopital Erasme; Charité Universitätsmedizin Berlin; Hospital General Gregorio Marañón; Hospital Universitari Vall d'Hebron; Hospital de Sant Joan de Deu- Hospital de la Santa Creu i Sant Pau; University Hospital Liege. | Germany, Spain, France, Italy, Belgium |
| 2024 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Aarhus University Hospital; Hospital Universitari Vall d'Hebron. | Denmark, Spain |
| 2024 | A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD | Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Hospital Universitari Vall d'Hebron; Institute of Hematology and Blood Transfusion, Prague. | Czechia, Spain, France |
| 2024 | Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment (DASTOP2) | Aarhus University Hospital; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor. | Denmark, France |
| 2024 | The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20): | Academic Medical Center Amsterdam; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Charité Universitätsmedizin Berlin; Erasmus MC: University Medical Center Rotterdam; Hospital Universitari Vall d'Hebron; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Ospedale San Raffaele di Milano; Maria Sklodowska-Curie National Research Institute of Oncology. | Germany, Spain, France, Italy, Netherlands, Poland |
| 2024 | A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | Academic Medical Center Amsterdam; Institute of Hematology and Blood Transfusion, Prague; Maria Sklodowska-Curie National Research Institute of Oncology; University Hospital Brno. | Czechia, Netherlands, Poland |
| 2024 | A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia | Gemeinschaftsklinikum Mittelrhein gGmbH; IRCCS Ospedale Pediatrico Bambino Gesù, Roma. | Germany, Italy |
| 2024 | Phase II study of the combination of ibrutinib and rituximab in treatment-naïve patients with marginal zone lymphoma | ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Hospices Civils de Lyon. | France, Italy |
| 2024 | Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus) | Aarhus University Hospital; Erasmus MC: University Medical Center Rotterdam. | Denmark, Netherlands |
| 2024 | Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan. | France, Italy |
| 2024 | STAND : A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises | Academic Medical Center Amsterdam; Assistance Publique Hôpitaux de Marseille; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; CUB-Hôpital Erasme; CUB-Hôpital Erasme; Charité Universitätsmedizin Berlin; Erasmus MC: University Medical Center Rotterdam; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; General Hospital of Athens "LAIKO"; Hospital Universitari Vall d'Hebron; IRCCS Ospedale San Raffaele di Milano. | Belgium, Germany, Spain, France, Greece, Italy, Netherlands |
| 2024 | Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis (BosuPeg) | Aarhus University Hospital; Karolinska University Hospital. | Denmark, Sweden |
| 2024 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY) | 251 Hellenic Air Force & VA General Hospital; Aarhus University Hospital; Academic Medical Center Amsterdam. | Denmark, Greece, Netherlands |
| 2024 | HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy | CHU de Lille; Ordensklinikum Linz Elisabethinen; Radboud University Medical Center Nijmegen; University Hospital Liège. | Belgium, France, Netherlands, Austria |
| 2024 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | Aarhus University Hospital; General Hospital of Athens "LAIKO". | Denmark, Greece |
| 2024 | An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects With Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies | AORN A Cardarelli; AOU - University Luigi Vanvitelli; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Charité Universitätsmedizin Berlin; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Hospital Universitari Vall d'Hebron; University Medical Center Utrecht; ; Universitätsklinikum Würzburg. | Germany, Spain, France, Italy, Netherlands |
| 2024 | BIOMARIN 270+A28:J38-302 :A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector¿ Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Hemophilia A Patients with Residual FVIII Levels = 1 IU/dL Receiving Prophylactic FVIII Infusions | AOU Careggi, Florence; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; CHU de Lille; Erasmus MC: University Medical Center Rotterdam; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; IRCCS Ospedale Pediatrico Bambino Gesù, Roma. | France, Italy, Netherlands |
| 2024 | Evaluation of a donor testing kit for the prediction of acute GVHD in patient receiving a Peripheral Blood Stem Cell allograft (Predictor 2) | Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; ; University Hospital Liège. | Belgium, France |
| 2024 | An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | ASST Sette Laghi - Ospedale di Circolo, Varese; AUSL Romagna- Presidio Ospedaliero di Ravenna; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; CHU de Lille; Hospital Universitari Vall d'Hebron; Hospital de Sant Joan de Deu- Hospital de la Santa Creu i Sant Pau; Maria Sklodowska-Curie National Research Institute of Oncology; University Clinical Centre; Universitätsklinikum Wurzburg. | Spain, France, Italy, Poland, Germany |
| 2024 | An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma clinical trial (TELLOMAK) | Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine; CHU de Lille; CHU de Montpellier; Charité Universitätsmedizin Berlin; Hospices Civils de Lyon; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Jules Bordet Institute; Maria Sklodowska-Curie National Research Institute of Oncology; Medical University of Vienna; University Hospital Liege. | Belgium, Germany, France, Italy, Poland |
| 2024 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | Aarhus University Hospital; University Hospital Leuven. | Belgium, Denmark |
| 2024 | A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib | AOU Policlinico Umberto I - Rome; AOUI Verona; ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Spedali Civili di Brescia; Ulm University Medical Center (UUMC); University Hospital Leuven; University Hospital Liege. | Belgium, Germany, France, Italy |
| 2024 | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation (MANGROVE) | AOU Policlinico Umberto I - Rome; AOUI Verona; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Jules Bordet Institute; Universitätsklinikum Heidelberg. | Belgium, Germany, France, Italy |
| 2024 | Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE) | Aarhus University Hospital; University Medical Center Utrecht. | Denmark, Netherlands |
| 2024 | A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy | Medical University of Vienna; Ordensklinikum Linz Elisabethinen; Radboud University Medical Center Nijmegen; Ulm University Medical Center (UUMC);; University Hospital Liège; University Medical Center Utrecht; Universitätsklinikum Hamburg-Eppendorf; Vilnius University Hospital Santaros Klinikos. | Belgium, Germany, Lithuania, Netherlands |
| 2024 | STEADFAST : A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy | Academic Medical Center Amsterdam; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; General Hospital of Athens "LAIKO"; Hospital Universitari Vall d'Hebron. | Spain, France, Greece, Netherlands |
| 2024 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Aarhus University Hospital; CHU de Montpellier. | Denmark, France |
| 2024 | Efficacy and safety of concizumab prophylaxis in patients with Hemophilia A or B Without Inhibitors (Explorer 8) | Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Varna Expert Center of coagulopathies and rare anemias. | Bulgaria, Italy |
| 2024 | A randomized, open-label, 2-arm, multicentre phase 3 study of venetoclax and azacitidine versus standard of care as maintenance therapy for patients with Acute Myeloid Leukemia in first remission after conventional chemotherapy | Academic Medical Center Amsterdam; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Institute of Hematology and Blood Transfusion- Prague; Karolinska University Hospital. | France, Netherlands, Sweden, Czechia |
| 2024 | A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | Foundation polyclinic University A. Gemelli - Rome; Hospital Universitari Vall d'Hebron; Maria Sklodowska-Curie National Research Institute of Oncology. | Spain, Italy, Poland |
| 2024 | Efficacy and safety of M281 in adult patients with warm form of autoimmune hemolytic anemia: a multicentre, randomized, double-blind, placebo-controlled clinical trial | IRCCS Ospedale San Raffaele di Milano; Institute of Hematology and Blood Transfusion- Prague; Leiden University Medical Center; Universitätsklinikum Heidelberg. | Germany, Italy, Netherlands |
| 2024 | Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT) | Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Spedali Civili di Brescia. | France, Italy |
| 2024 | Phase 2 study of daratumumab monotherapy in previously untreated patients with stage 3B light chain (AL) amyloidosis | Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Foundation IRCCS Polyclinic San Matteo, Pavia; University Medical Center Utrecht. | France, Italy, Netherlands |
| 2024 | A Multicenter, open-label study to evaluate the safety, efficacy, pharmacokinetcs and pharmacodynamics of Emicizumab in patients with mild or moderate Hemophilia A without FVIII Inhibitors | Academic Medical Center Amsterdam; University Hospital Leuven. | Belgium, Netherlands |
| 2024 | A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) | AOU Policlinico Umberto I - Rome; AOUI Verona; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Fondazione IRCCS San Gerardo dei Tintori; University Hospital Liege. | France, Italy, Belgium |
| 2024 | A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001) | CUB-Hôpital Erasme; IRCCS Ospedale Pediatrico Bambino Gesù, Roma. | Belgium, Italy |
| 2024 | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. (SYMPHONY-1) | AOU Federico II - Naples; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; CHU de Lille; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Hospital Universitari Vall d'Hebron; Istituto Scientiï¬co Romagnolo per lo Studio e la Cura dei Tumori (IRST) s.r.l. IRCCS; Maria Sklodowska-Curie National Research Institute of Oncology; Spedali Civili di Brescia; University Hospital Leuven; University of Debrecen. | Belgium, Spain, France, Hungary, Italy, Poland |
| 2024 | SLSG18-301 A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy | AUSL Romagna- Presidio Ospedaliero di Ravenna; General Hospital of Athens "LAIKO"; University Clinical Centre. | Greece, Italy, Poland |
| 2024 | DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma | AUSL Romagna- Presidio Ospedaliero di Ravenna; Maria Sklodowska-Curie National Research Institute of Oncology; Spedali Civili di Brescia. | Italy, Poland |
| 2024 | A randomized, double-blind, placebo-controlled multi-centre phase 3 study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Institute of Hematology and Blood Transfusion- Prague; Karolinska University Hospital; Radboud University Medical Center Nijmegen; Ulm University Medical Center (UUMC). | Germany, France, Netherlands, Sweden, Czechia |
| 2024 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | University Medical Center Utrecht; Universitätsklinikum Hamburg-Eppendorf; Vilnius University Hospital Santaros Klinikos. | Germany, Lithuania, Netherlands |
| 2024 | Gilead_5F9009_ENHANCE_Magrolimab: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome | ASST Sette Laghi - Ospedale di Circolo, Varese; Fondazione IRCCS San Gerardo dei Tintori; Spedali Civili di Brescia; Universitätsklinikum Carl Gustav Carus. | Germany, Italy |
| 2024 | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma (POLAR BEAR) | AOUI Verona; Aarhus University Hospital; Karolinska University Hospital. | Denmark, Italy, Sweden |
| 2024 | A randomized, double-blind, phase 3 study evaluating the safety and efficacy of venetoclax in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (higher-risk MDS) | Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Institute of Hematology and Blood Transfusion- Prague; Karolinska University Hospital; Radboud University Medical Center Nijmegen. | France, Netherlands, Sweden, Czechia |
| 2024 | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (ECHELON-3) | Aarhus University Hospital; Universitair Ziekenhuis Antwerpen. | Belgium, Denmark |
| 2024 | A randomized, unblinded, active-controlled, multicentre phase 3 study evaluating the safety and efficacy of crovalimab compared to eculizumab in adult and adolescent patients with PNH currently receiving treatment with complement system inhibitors | AOU Federico II - Naples; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Copenhagen University Hospital - Rigshospitalet; Institute of Hematology and Blood Transfusion- Prague; Radboud University Medical Center Nijmegen; Ulm University Medical Center (UUMC). | Germany, France, Italy, Netherlands, Czechia, Denmark |
| 2024 | A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. (COMMODORE 2) | Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Hospital de Sant Joan de Deu- Hospital de la Santa Creu i Sant Pau; Vilnius University Hospital Santaros Klinikos. | Lithuania, Spain, Italy |
| 2024 | A Randomized, Open-Label, Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis | AOU Policlinico Umberto I - Rome; ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Fondazione IRCCS San Gerardo dei Tintori; General Hospital of Athens "LAIKO"; University Clinical Centre. | France, Greece, Italy, Poland |
| 2024 | A Randomized, Open-Label, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Alone in Subjects with Myelofibrosis | ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; General Hospital of Athens "LAIKO"; University Hospital Leuven; University Hospital Liège; University Medical Center Utrecht. | Belgium, France, Greece, Italy, Netherlands |
| 2024 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post- PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib | ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Hospital Universitari Vall d'Hebron. | Spain, France, Italy |
| 2024 | Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) | General Hospital of Athens "LAIKO"; University Clinical Centre. | Greece, Poland |
| 2024 | A Phase 3, double-blind, multicenter study to evaluate the efficacy and safety of CAEL-101 and plasma cell dyscrasia treatment versus placebo and plasma cell dyscrasia treatment in plasma cell dyscrasia treatment-naive patients with mayo stage IIIb AL Amyloidosis | CHU de Limoges; Foundation IRCCS Polyclinic San Matteo, Pavia; General Hospital of Athens "LAIKO"; Hospital Universitari Vall d'Hebron; Hospital Universitario Virgen del Rocio; Jules Bordet Institute; Medical University of Vienna; University Clinical Centre; University Hospital Leuven; Universitätsklinikum Hamburg-Eppendorf; Universitätsklinikum Heidelberg; Universitätsklinikum Wurzburg. | Belgium, Germany, Spain, France, Greece, Italy, Poland, Austria |
| 2024 | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | Aarhus University Hospital; Medical University of Vienna. | Denmark, Austria |
| 2024 | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIa | CHU de Limoges; Foundation IRCCS Polyclinic San Matteo, Pavia; General Hospital of Athens "LAIKO"; Hospital Universitari Vall d'Hebron; Hospital Universitario Virgen del Rocio; Jules Bordet Institute; Medical University of Vienna; University Clinical Centre; University Hospital Leuven; Universitätsklinikum Hamburg-Eppendorf; Universitätsklinikum Heidelberg; Universitätsklinikum Wurzburg. | Belgium, Germany, Spain, France, Greece, Italy, Poland, Austria |
| 2024 | A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients | AOU Policlinico Umberto I - Rome; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine; CHU de Lille; Charité Universitätsmedizin Berlin; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Ospedale San Raffaele di Milano; Medical University of Vienna; Ospedale Papa Giovanni XXIII di Bergamo; Spedali Civili di Brescia; Ulm University Medical Center (UUMC); Universitätsklinikum Leipzig. | Germany, France, Italy |
| 2024 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study of ravulizumab in adult and adolescent participants who have thrombotic microangiopathy (TMA) after hematopoietic stem cell transplant (HSCT) | Ulm University Medical Center (UUMC); University Hospital Liège. | Belgium, Germany |
| 2024 | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib | ASST Sette Laghi - Ospedale di Circolo, Varese; HUS Helsinki University Hospital, Hospital District of Helsinki and Uusimaa; Hospital Universitari Vall d'Hebron. | Spain, Finland, Italy |
| 2024 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis | AOUI Verona; ASST Sette Laghi - Ospedale di Circolo, Varese; HUS Helsinki University Hospital, Hospital District of Helsinki and Uusimaa; Hospital Universitari Vall d'Hebron. | Spain, Finland, Italy |
| 2024 | Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis (SENTRY) | Aarhus University Hospital; University Hospital Leuven | Belgium, Denmark |
| 2024 | Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients (EMN26) | Academic Medical Center Amsterdam; Spedali Civili di Brescia. | Italy, Netherlands |
| 2024 | Safety, efficacy and exposure of subcutaneously administered NNC0365-3769 (Mim8) prophylaxis in children with haemophilia A with or without FVIII inhibitors | Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Hospital de Sant Joan de Déu. | Spain, France |
| 2024 | A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor | ASST Sette Laghi - Ospedale di Circolo, Varese; AUSL Romagna- Presidio Ospedaliero di Ravenna; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Azienda Ospedaliero-Universitaria S. Anna di Ferrara; Fondazione IRCCS San Gerardo dei Tintori; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; University Hospital Liège; University Hospital Liège; Universitätsklinikum Leipzig. | Belgium, Germany, France, Italy |
| 2024 | A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients | ASST Sette Laghi - Ospedale di Circolo, Varese; Azienda Ospedaliero-Universitaria S. Anna di Ferrara; Fondazione IRCCS San Gerardo dei Tintori; General Hospital of Athens "LAIKO"; Hospital Universitari Vall d'Hebron; Spedali Civili di Brescia; University Hospital Leuven; University Hospital Liège; Universitätsklinikum Hamburg-Eppendorf. | Belgium, Germany, Spain, Greece, Italy |
| 2024 | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis (EMN27) | CHU de Limoges; Foundation IRCCS Polyclinic San Matteo, Pavia; General Hospital of Athens "LAIKO"; University Medical Center Utrecht; Universitätsklinikum Heidelberg. | Germany, France, Greece, Italy, Netherlands |
| 2024 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1) | Aarhus University Hospital; University Hospital Leuven. | Belgium, Denmark |
| 2024 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1) | AOU Policlinico Umberto I - Rome; ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Universitätsklinikum Wurzburg. | France, Italy, Germany |
| 2024 | Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A (XTEND-ed) | Academic Medical Center Amsterdam; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; CHU de Lille; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Hospices Civils de Lyon; Hospital de Sant Joan de Deu- Hospital de la Santa Creu i Sant Pau; Hospital de Sant Joan de Déu; IRCCS Ospedale Pediatrico Bambino Gesù, Roma; University Medical Center Utrecht. | Spain, France, Italy, Netherlands |
| 2024 | A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor treatment Ineligible Myelofibrosis | AUSL Romagna- Presidio Ospedaliero di Ravenna; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; University Hospital Liège. | Belgium, Italy |
| 2024 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321) | ASST Sette Laghi - Ospedale di Circolo, Varese; Aarhus University Hospital; CHU de Lille; Hospital Universitari Vall d'Hebron; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) s.r.l. IRCCS. | Denmark, Spain, France, Italy |
| 2024 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7) | AOU Policlinico Umberto I - Rome; Maria Sklodowska-Curie National Research Institute of Oncology; University Clinical Centre. | Italy, Poland |
| 2024 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Tafasitamab + Lenalidomide + Rituximab vers Lenalidomide + rituximab in patients with RR Folicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma (INCMOR0208-301) | General Hospital of Athens "LAIKO"; Jules Bordet Institute; Maria Sklodowska-Curie National Research Institute of Oncology; Universitätsklinikum Wurzburg. | Belgium, Greece, Poland, Germany |
| 2024 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (RADAR) | Aarhus University Hospital; Academic Medical Center Amsterdam. | Denmark, Netherlands |
| 2024 | A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions | AOU Policlinico Umberto I - Rome; AOUI Verona; ASST Sette Laghi - Ospedale di Circolo, Varese; Ordensklinikum Linz Elisabethinen; Spedali Civili di Brescia; University Hospital Leuven; University Hospital Liège; University Hospital Liège; University Hospital RWTH Aachen. | Belgium, Germany, Italy |
| 2024 | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | AUSL-IRCCS di Reggio Emilia; Aarhus University Hospital; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Foundation IRCCS Polyclinic San Matteo, Pavia; Hospital Universitari Vall d'Hebron; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Ospedale San Raffaele di Milano; Maria Sklodowska-Curie National Research Institute of Oncology; Spedali Civili di Brescia; Ulm University Medical Center (UUMC); University Hospital Brno. | Czechia, Germany, Denmark, Spain, France, Italy, Poland |
| 2024 | APPLY rollover CLNP023C12001B: An open label, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have completed PNH phase 2 and phase 3 studies with iptacopan | AOU Policlinico Umberto I - Rome; Radboud University Medical Center Nijmegen; Universitätsklinikum Hamburg-Eppendorf; Vilnius University Hospital Santaros Klinikos. | Germany, Italy, Lithuania, Netherlands |
| 2024 | MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients (ARES) | Ordensklinikum Linz Elisabethinen; University Hospital Liège. | Belgium, Austria |
| 2024 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia | AOU Modena; Academic Medical Center Amsterdam; Aghia Sophia Children's Hospital; Assistance Publique Hôpitaux de Marseille; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Charité Universitätsmedizin Berlin; Copenhagen University Hospital - Rigshospitalet; Erasmus MC: University Medical Center Rotterdam; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; General Hospital of Athens "LAIKO"; Hospices Civils de Lyon; Hospital Universitari Vall d'Hebron; Hospital Universitario Virgen del Rocio; University Medical Center Utrecht. | Germany, Spain, France, Greece, Italy, Netherlands, Denmark |
| 2024 | GS-US-546-5857 Enhance2: A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician's Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia | AOU Ospedali Riuniti "Umberto I - G.M. Lancisi-G. Salesi"; ASST Sette Laghi - Ospedale di Circolo, Varese; Universitätsklinikum Carl Gustav Carus. | Germany, Italy |